



AnaptysBio

*Leader in SHM for
Antibody Therapeutics*

FOR IMMEDIATE RELEASE

January 12, 2009

**ANAPTYSBIO ADDS THREE TO SENIOR MANAGEMENT TEAM
TO SUPPORT GROWING PIPELINE
OF THERAPEUTIC ANTIBODY PROGRAMS**

Experts in antibody engineering and development, business development, and project and alliance management recruited to advance Somatic Hypermutation (SHM) discovery and optimization technology applications

SAN DIEGO, CA – AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company, today announced the appointment of three recognized experts in antibody therapeutics, business development, and project and alliance management to its senior management team as part of its strategic growth plan for 2009 and beyond.

The key hires are David King, Ph.D., vice president, research, formerly of Medarex; Hamza Suria, vice president, corporate development, joining from Maxygen; and Steve Neben, Ph.D., senior director, project and alliance management, previously with XOMA.

“Following our successful \$34 million Series B financing at the end of 2007, we set plans in motion to expand our product pipeline with a significantly greater number of antibody discovery programs. We’ve also been working to pursue multiple business and partnering opportunities,” said Tom Smart, chairman and chief executive officer of AnaptysBio. “This required recruiting the right mix of talent to ensure we take advantage of the lead we have in using SHM to generate and optimize antibodies to build our product pipeline and through partnerships the pipelines of others. David, Hamza and Steve were selected for their obvious credentials and also how they fit with our entrepreneurial and fast-moving culture.”

King brings more than three decades of R&D experience in therapeutic antibodies to the team. Prior to AnaptysBio, he was senior director, molecular biology & biochemistry for Medarex where he was involved in the design and selection of therapeutic antibodies and development of a new class of antibody-drug conjugates. In his career in antibody engineering and antibody therapeutics, he has been involved in the design and development of three FDA-approved antibody products and several other clinical stage antibodies. Prior to joining Medarex, King was at Coulter Pharmaceuticals, later acquired by Corixa, where he was part of the team that

successfully re-filed the BLA for Bexxar®, a radiolabelled antibody for therapy of non-Hodgkin's lymphoma. Previously, he worked at Celltech in the UK, where he was involved in the design and development of Mylotarg®, an antibody-drug conjugate for therapy of acute myeloid leukemia. He was the lead inventor of Cimzia®, a PEGylated antibody fragment for therapy of autoimmune diseases. King received his bachelor's of science from the University of Warwick and his doctorate from the University of Surrey in the U.K., and was a Glaxo Group Research postdoctoral fellow.

Suria has extensive experience in business development, as well as technical and product development matters related to therapeutic antibodies and other biologics. Prior to AnaptysBio, he was senior director, business development at Maxygen where he was responsible for partnering and alliance management of next-generation protein therapeutics with Roche, Sanofi-Aventis, Bayer, Astellas and others. Before Maxygen, Suria was director of business development at Diabetogen Biosciences with responsibility for corporate partnerships. He also held various business development positions at Viron Therapeutics and the Robarts Research Institute. Suria holds a bachelor's of science in biochemistry from Kalamazoo College, an Master's of Science in immunology from the University of Western Ontario and an Executive MBA from the Richard Ivey School of Business. He is an ASAP-certified Alliance Management Professional.

Neben is an expert in immunology and the discovery and development of biologics, including therapeutic antibodies. Prior to AnaptysBio, he was director of project and alliance management at XOMA Ltd where he managed internal pipeline projects and therapeutic antibody discovery and development collaborations with Schering-Plough, Takeda Pharmaceutical Company Limited, and Lexicon Pharmaceuticals. Before XOMA, he was a senior scientist and responsible for respiratory diseases drug discovery at Bayer Biotechnology and staff scientist at Wyeth/Genetics Institute. He received both a bachelor's of arts and doctorate in biophysics and medical physics from University of California, Berkeley and was a post-doctoral fellow at Harvard Medical School. He is a PMI-certified Project Management Professional.

About AnaptysBio

Founded in 2005, AnaptysBio, Inc is a privately-held therapeutic antibody product company and the leader in the use of somatic hypermutation, or SHM, for antibody discovery and optimization. SHM is the body's natural process for generating potent antibodies to fight disease. The Company's SHM-Platform™ utilizes the key components of SHM and other techniques to generate antibodies for therapeutic applications through an iterative process of natural evolution and high-throughput selection – a process that has been referred to as “naturalizing” antibodies. This versatile platform can be used both to discover and optimize antibodies directed at specific disease targets and also affinity mature existing antibodies to improve their binding properties. The company has established broad intellectual property around the use of SHM for therapeutic antibody applications, and is currently building a pipeline of novel therapeutic antibody product candidates. For more information, visit www.anaptysbio.com.

Contacts:

Gable PR – 1-877-251-3888

Erin Koch
erin.koch@gablepr.com
Cell: 619-246-9249

Tom Gable
tom@gablepr.com
Cell: 619-251-3881